Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
NCT07403669
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Acute MI
- Heart Failure
- Diabetes Mellitus
- Kidney Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Aventyn, Inc.
- Last updated on ClinicalTrials.gov
- February 12, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 2
- Gilbert Cardiology · Gilbert, AZ
- Arizona Heart Foundation · Phoenix, AZ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.